Millendo Therapeutics, Inc. (MLND): Price and Financial Metrics


Millendo Therapeutics, Inc. (MLND): $1.06

-0.06 (-5.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MLND Stock Summary

  • Millendo Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.5% of US listed stocks.
  • With a year-over-year growth in debt of 570.28%, Millendo Therapeutics Inc's debt growth rate surpasses 96.28% of about US stocks.
  • As for revenue growth, note that MLND's revenue has grown -150.17% over the past 12 months; that beats the revenue growth of only 0.32% of US companies in our set.
  • MLND's SEC filings can be seen here. And to visit Millendo Therapeutics Inc's official web site, go to www.ovascience.com.

MLND Stock Price Chart Interactive Chart >

Price chart for MLND

MLND Price/Volume Stats

Current price $1.06 52-week high $2.77
Prev. close $1.12 52-week low $0.92
Day low $1.06 Volume 1,912,600
Day high $1.13 Avg. volume 1,516,167
50-day MA $1.17 Dividend yield N/A
200-day MA $1.67 Market Cap 20.19M

Millendo Therapeutics, Inc. (MLND) Company Bio


Millendo Therapeutics, Inc. provides health care services. The Company develops treatments for endocrine diseases. Millendo Therapeutics serves customers in the United States and France.


MLND Latest News Stream


Event/Time News Detail
Loading, please wait...

MLND Latest Social Stream


Loading social stream, please wait...

View Full MLND Social Stream

Latest MLND News From Around the Web

Below are the latest news stories about Millendo Therapeutics Inc that investors may wish to consider to help them evaluate MLND as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with a look at the pre-market stock market movers for Wednesday with the biggest winners and losers.

William White on InvestorPlace | June 23, 2021

Tempest and Millendo Announce Stockholder Approval of Merger

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”SOUTH SAN FRANCISCO, Calif. and ANN ARBOR, Mich., June 22, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, and Millendo Therapeutics, Inc. (Nasdaq: MLND) (“Millendo”), announced today the results for the proposals voted upon by Millendo stockholders at a Special Meeting on June

Yahoo | June 22, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates COHR, SNX, PFBI, MLND; Shareholders are Encouraged to Contact the Firm

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Coherent, Inc. (NASDAQ: COHR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to II-VI Incorporated for $220.00 in cash and 0.91 shares of II-VI common stock for each Coherent share. If you are a Coherent shareholder, click here to learn more about your rights and options. SY

Yahoo | June 11, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds MLND, DISCA, FOE and MSGN Shareholders About Its Ongoing Investigations

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212) 682-3025(888) [email protected] Millendo Therapeutics, Inc. (NASDAQ: MLND) WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by

Yahoo | June 9, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CNST, FMBI, SWN, ENVB, MLND; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | June 5, 2021

Read More 'MLND' Stories Here

MLND Price Returns

1-mo N/A
3-mo -93.75%
6-mo -96.82%
1-year -95.92%
3-year -99.47%
5-year -99.92%
YTD -96.70%
2020 -68.25%
2019 -15.22%
2018 -62.14%
2017 -8.50%
2016 -84.34%

Continue Researching MLND

Want to see what other sources are saying about Millendo Therapeutics Inc's financials and stock price? Try the links below:

Millendo Therapeutics Inc (MLND) Stock Price | Nasdaq
Millendo Therapeutics Inc (MLND) Stock Quote, History and News - Yahoo Finance
Millendo Therapeutics Inc (MLND) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.888 seconds.